The research, led by Paige W. Lake of the Health Outcomes and Behavior program at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, together with colleagues at Moffitt and New York University’s Grossman School of Medicine, was published in Supportive Care in Cancer. Rather than surveying a small, selected clinic population, the team tapped into something far more powerful: a large-scale electronic patient questionnaire administered at clinical intake, paired with cancer registry data that documented each patient’s diagnosis and treatment. This design allowed the investigators to examine, across thousands of consecutive patients, who wanted future children and who, among those wanting or uncertain about children, expressed interest in meeting with a fertility specialist.

The scale of the dataset is one of its defining strengths. A total of 4,847 adolescent and young adult patients completed the questionnaire, a group that was 62 percent female with an average age of 32 years. The questionnaire captured self-reported physical and mental health alongside two deceptively simple questions: whether the patient desired future children, and whether they would be interested in a consultation with a fertility specialist. Linking these responses to registry-recorded cancer characteristics, including tumor type and treatment modalities such as chemotherapy, hormone therapy, and transfusions, gave the researchers a multidimensional picture of reproductive priorities at the moment of diagnosis, before treatment had begun to reshape them.

The statistical approach was correspondingly rigorous. To identify the factors associated with the desire for future children, the team used multinomial regression, an analysis that can distinguish between patients who want children, those who do not, and those who are genuinely undecided, rather than collapsing uncertainty into a binary answer. A second, binary regression analysis was then restricted to the subset of patients who wanted children or were unsure, asking which characteristics predicted interest in a fertility consultation. This two-stage design matters because it separates two distinct clinical questions: who values the possibility of biological parenthood, and who wants expert help in protecting it. The answers, as it turned out, did not overlap neatly.

The first stage produced a pattern that will feel intuitive to anyone who has watched family-building decisions unfold, but the effect sizes are striking. Female patients were significantly less likely than male patients to report wanting future children, with an odds ratio of 0.56, meaning their odds were nearly half those of men in the cohort. Age exerted a strong and steady effect: each additional year of age reduced the odds of wanting children by roughly 19 percent, with an odds ratio of 0.81 per year. And patients who already had children were far less likely to want more, with an odds ratio of 0.34, less than half the odds of child-free patients. In a cohort where the average patient was 32, these gradients mean that reproductive desire was concentrated among the youngest, child-free patients, precisely the group with the longest reproductive runway ahead of them and the most to lose from gonadotoxic treatment.

The second stage of the analysis revealed who, among those wanting or uncertain about children, actually wanted to sit down with a fertility specialist, and here the pattern inverted in a clinically important way. Older patients were more likely, not less, to express interest in a consultation, with an odds ratio of 1.04 per year of age. Women were more interested than men, with an odds ratio of 1.39. Diagnosis mattered as well: patients with breast cancer were more than two and a half times as likely to want a consultation, with an odds ratio of 2.65, and lymphoma patients nearly twice as likely, with an odds ratio of 1.99. Treatment type left its own signature. Those receiving hormone therapy had 73 percent higher odds of wanting a consultation, and patients who had received transfusions showed a markedly elevated estimate as well, with an odds ratio of 3.23, though the wide confidence interval around that figure, spanning 0.86 to 12.21, reflects a smaller number of patients in that category and demands cautious interpretation.

Why would the youngest patients, who most want children, be less inclined to seek specialist input, while older patients and those with breast cancer or lymphoma seek it out? Part of the answer likely lies in the structure of cancer care itself. Breast cancer and lymphoma are treated by oncology teams for whom fertility preservation referral has become increasingly routinized, supported by dedicated oncofertility programs and, more recently, by updated clinical guidelines from the American Society of Clinical Oncology that call for discussing fertility preservation options with patients before gonadotoxic therapy begins. Patients with these diagnoses are more likely to be asked the right questions at the right moment. Younger patients, meanwhile, may be processing an overwhelming new diagnosis, and the assumption, by clinicians or by the patients themselves, that youth equals fertility, can quietly close a door that should have been opened.

The biology underlying these conversations is unforgiving in its timing. Chemotherapy agents, particularly alkylating drugs and platinum compounds such as cisplatin, damage the rapidly dividing cells of the ovary and the spermatogonial stem cells of the testis. Pelvic and cranial radiation can disrupt the hypothalamic-pituitary-gonadal axis. In women, the ovarian reserve is finite and cannot regenerate, so a treatment that destroys a large fraction of remaining follicles can precipitate premature ovarian insufficiency, a risk that population-based studies have documented at elevated rates in young survivors of non-gynecological cancers. In men, sperm production can sometimes recover, but azoospermia after treatment is common enough that sperm cryopreservation before therapy remains the single most established preservation option. Oocyte and embryo cryopreservation, ovarian tissue banking, and ovarian suppression strategies offer women parallel but more complex pathways, each requiring days to weeks of lead time that a fast-growing cancer may not easily spare.

What makes the new findings actionable is that they identify exactly where the referral pipeline leaks. The authors conclude that there is a need to systematically address and offer fertility consultation to all adolescent and young adult patients prior to the initiation of treatment, rather than relying on ad hoc conversations whose frequency depends on diagnosis, age, and sex. The data suggest that a triage model keyed to diagnosis or age would miss patients who want help: a 38-year-old woman with breast cancer is more likely to ask for a consultation than a 24-year-old man with a diagnosis less associated with oncofertility services, even though the younger man may have the stronger desire for future biological children and the greater cumulative reproductive risk across his remaining life. Prior research in this field has consistently shown that fertility-related distress is common among young survivors, that pretreatment counseling is associated with improved quality of life, and that unaddressed reproductive concerns can influence later treatment decisions, including adherence to endocrine therapy in young breast cancer survivors who must weigh years of hormonal suppression against their shrinking window for pregnancy.

The study’s authors are careful to note that sociodemographic, clinical, and psychosocial factors warrant additional study and future intervention development to ensure that fertility needs are met, and the dataset has limitations inherent to its design: responses were self-reported at a single moment of acute stress, and the transfusion finding in particular rests on a small subgroup. But the central message survives those caveats intact. Nearly five thousand young patients told researchers, in their own words at the moment of diagnosis, that parenthood remains a live and urgent question for many of them, and that the desire for children does not automatically translate into access to the specialists who can protect it. Closing that gap will not require new drugs or new technology; the preservation options already exist. It requires making one conversation universal, systematic, and early, offered to every adolescent and young adult before the first infusion, so that the decision about whether to pursue fertility preservation belongs to the patient rather than to chance, diagnosis, or whoever happens to remember to ask.

Subject of Research: Desire for future children and interest in fertility specialist consultation among adolescent and young adult cancer patients

Article Title: Desire for future children and interest in consultation with a fertility specialist among adolescent and young adult (AYA) cancer patients

Article References: Lake, P. W., Zhao, Y., Amorrortu, R. P., Quinn, G. P., Rollison, D. E., & Vadaparampil, S. T. (2026). Desire for future children and interest in consultation with a fertility specialist among adolescent and young adult (AYA) cancer patients. Supportive Care in Cancer, 34(10), Article 1060. https://doi.org/10.1007/s00520-026-11313-6

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11313-6

Keywords: adolescent and young adult oncology, fertility preservation, oncofertility, cancer, infertility, fertility consultation, breast cancer, lymphoma, reproductive health, patient-reported outcomes, supportive care, cancer registry

The study was conducted by a team of nursing and hematology researchers affiliated with Tehran University of Medical Sciences, drawing participants from the Hematology-Oncology and Stem Cell Transplantation Research Center. The women, whose mean age was approximately 34.7 years with a standard deviation of about 9 years, completed a sociodemographic profile, a researcher-developed Fertility Knowledge Questionnaire scored out of 10, and the Attitude Toward Fertility and Childbearing Scale, a validated psychometric instrument. The researchers then used multivariable linear regression to identify which characteristics independently predicted knowledge and attitude scores, an approach that allowed them to separate the effects of age, education, marital status, economic circumstances, and reproductive history from one another.

The headline numbers are sobering. The mean fertility knowledge score was 4.56 out of 10, with a standard deviation of 1.92, placing the average survivor well below the midpoint of the scale. More alarming than the aggregate score was the pattern of specific deficits. When asked about the appropriate timing for pregnancy after transplantation, 92.3 percent of respondents answered incorrectly. When asked about treatment-related reproductive risks, 94.7 percent got the answer wrong. These are not obscure clinical details; the recommended interval before attempting conception after transplant, and the realistic probability of spontaneous pregnancy given gonadal damage, are precisely the facts a survivor needs in order to plan contraception, seek specialist care, or avoid an unplanned and potentially dangerous pregnancy.

Against this backdrop of ignorance, the survivors’ attitudes toward parenthood were remarkably warm. The mean attitude score was 63.25, with a standard deviation of 10.73, which the authors characterize as relatively positive. Nearly half of the participants, 47.4 percent, expressed a desire for future children. Taken together, the two findings sketch a paradox: a population that wants children but does not understand the biological constraints, risks, and timelines that govern whether and when those children might be safely conceived after a transplant.

Perhaps the most intriguing statistical result is a significant inverse correlation between knowledge and attitude scores, with a Pearson coefficient of minus 0.334 and a p-value below 0.01. In plain terms, women who knew more about their post-transplant fertility tended to hold less optimistic attitudes toward childbearing, while those with greater knowledge gaps were more hopeful. The authors interpret this cautiously, suggesting that enhanced awareness of reproductive risk might temper what they call reproductive optimism. The correlation is cross-sectional, so causality cannot be established; it is equally possible that women who have already absorbed difficult information about their fertility have emotionally adjusted their expectations downward. Either way, the finding challenges the common assumption that education alone will uniformly empower and reassure patients.

The regression models also revealed who knew more and who wanted more. For knowledge, the model accounted for a substantial 46 percent of the variance, with older age, holding a master’s degree, being divorced, and having health insurance each independently predicting higher scores. The education effect is unsurprising, but the insurance finding hints at structural inequities in how survivorship information is delivered: women with coverage may have more frequent follow-up encounters and better access to counseling. For attitudes, the model explained 31 percent of the variance, with younger age, having fewer existing children, and reporting superior economic status predicting more positive views of future childbearing. Younger women, with more reproductive years potentially ahead of them, and women who have not yet completed their families, logically attach more value to future parenthood.

The clinical context makes these gaps more dangerous than they might first appear. Pregnancy after hematopoietic cell transplantation is possible, and case series from large registries such as the Center for International Blood and Marrow Transplant Research have documented successful outcomes, but it is considered high risk for both mother and fetus. Survivors face elevated rates of ovarian failure, and those who do conceive require careful obstetric surveillance for complications including relapse, graft-versus-host disease flare, and the teratogenic potential of ongoing medications such as immunosuppressants. A survivor who does not know that pregnancy should be deferred for a specified period after transplant, or that her residual ovarian reserve may be minimal, could inadvertently conceive during a window when the risks are highest, or conversely abandon hope of biological motherhood without ever exploring options such as donor oocytes or previously cryopreserved embryos.

The timing of information delivery is a central theme of the study’s implications. The authors argue that structured, multidisciplinary, and psychologically informed fertility counseling should be incorporated into routine survivorship care, and ideally initiated before conditioning regimens begin. This aligns with a broader movement in oncofertility: fertility preservation options for women facing gonadotoxic therapy, including oocyte and embryo cryopreservation and ovarian tissue freezing, are time-sensitive and must be discussed in the narrow interval between diagnosis and treatment. Once the transplant is complete and ovarian function has been lost, the menu of options narrows dramatically. Prior research has shown that women often report greater vulnerability than men when confronting treatment-induced infertility, and that fertility-related distress among transplant survivors persists for a decade or more after the procedure.

The study’s framework draws on established health psychology models, including the Health Belief Model and Protection Motivation Theory, which posit that perceived susceptibility and perceived severity shape whether people adopt protective behaviors. In this light, the inverse knowledge-attitude correlation takes on additional meaning: survivors who perceive themselves as highly susceptible to infertility and pregnancy complications may rationally lower their childbearing aspirations, while those who underestimate the threat maintain optimism that may not match their clinical reality. Effective counseling, the authors imply, must do more than transfer facts; it must help patients integrate accurate risk information into their life plans without extinguishing legitimate hope, since spontaneous pregnancies and assisted reproduction outcomes do occur in this population.

The findings carry weight beyond Iran. Hematopoietic stem cell transplantation is performed tens of thousands of times each year worldwide, and the population of long-term survivors continues to expand as survival rates improve. Survivorship guidelines in Europe and North America increasingly call for routine assessment of reproductive concerns, but implementation remains uneven, and fertility discussions are frequently omitted from post-transplant follow-up, particularly for patients who are older, unmarried, or already parents at the time of treatment. This study suggests that such omissions leave a measurable knowledge vacuum. The authors’ call for psychologically informed counseling acknowledges a further nuance: information that arrives without emotional support can itself be distressing, and the goal of survivorship care is not simply to raise scores on a questionnaire but to equip women to make reproductive decisions that reflect both their medical reality and their personal values. For the nearly half of surveyed survivors who still hope for children, that kind of informed, compassionate guidance may determine whether their reproductive futures are chosen deliberately or left to chance.

Subject of Research: Fertility knowledge and childbearing attitudes among female hematopoietic stem cell transplantation survivors

Article Title: Fertility-related knowledge and childbearing attitudes among female survivors of hematopoietic stem cell transplantation: a cross-sectional study

Article References: Dehghan, A. H., Vafaeinezhad, F., Chekeni, A. M., Ghane, G., rozveh, A. K., & Vaezi, M. (2026). Fertility-related knowledge and childbearing attitudes among female survivors of hematopoietic stem cell transplantation: a cross-sectional study. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764-026-02134-x

Image Credits: AI Generated

DOI: 10.1007/s11764-026-02134-x

Keywords: hematopoietic stem cell transplantation, fertility knowledge, childbearing attitudes, cancer survivorship, fertility preservation, gonadotoxicity, premature ovarian insufficiency, reproductive counseling, women's health, oncofertility, cross-sectional study, survivorship care

The research team, led by Phi Y. Huynh of Taipei Medical University and the University Medical Center in Ho Chi Minh City, systematically searched four major biomedical databases: PubMed, Embase, Scopus, and the Cochrane Library. After screening the literature according to PRISMA 2020 reporting standards, the investigators pooled data from 34 studies encompassing a remarkable 10,216 premenopausal women with breast cancer. The sheer scale of the dataset gives the findings unusual authority in a field where individual studies have often been small, heterogeneous, and sometimes contradictory.

The central message is sobering. Using random-effects models and restricted maximum likelihood estimation with logit transformation, the researchers calculated the probability of ovarian function recovery at three critical time points. Twelve months after the end of chemotherapy, only 30.4 percent of women had regained ovarian function, with a wide 95 percent confidence interval of 17.5 to 47.3 percent. By 24 months, the figure rose to 38.5 percent, and at five years it reached 43.4 percent, though the confidence intervals at these later timepoints were extremely broad, spanning from 15.6 to 68.1 percent and from 9.4 to 84.9 percent respectively. In other words, even after half a decade, most women who lost ovarian function to chemotherapy had not recovered it.

The analysis also quantified timing for the first time in a pooled framework. The mean time to ovarian recovery across the included studies was 12.3 months, with a 95 percent confidence interval of 8.7 to 15.9 months. This figure carries practical implications for patients and clinicians alike. A woman whose periods have not returned within a year of finishing chemotherapy should understand that the clock has not necessarily run out, but she should also recognize that the odds of a late rebound diminish considerably the longer amenorrhea persists.

Perhaps the most clinically actionable findings concern predictors of recovery. Older age emerged as a dominant and statistically robust negative factor: women in older age groups had roughly a quarter of the odds of recovering ovarian function compared with their younger counterparts, with a pooled odds ratio of 0.25 and a confidence interval of 0.12 to 0.50. The biological explanation is straightforward. Chemotherapy depletes the finite pool of primordial follicles that constitutes the ovarian reserve, and a woman who enters treatment with fewer follicles simply has less capacity for regeneration. Longer chemotherapy duration also independently reduced the odds of recovery, with an odds ratio of 0.68 and a confidence interval of 0.50 to 0.92, reflecting the cumulative gonadotoxicity of extended alkylating-agent exposure, particularly cyclophosphamide.

The story of anti-Müllerian hormone, or AMH, proved more nuanced. Produced by small growing follicles, AMH is widely regarded as the most reliable circulating biomarker of ovarian reserve. In individual studies included in the review, higher pretreatment AMH levels appeared to predict better recovery of ovarian function, aligning with a substantial body of prior evidence that AMH measurements can identify women at lower risk of permanent treatment-induced menopause. Yet when the authors pooled these estimates, the association did not reach statistical significance. The likely culprits are heterogeneity in AMH assay platforms, variable timing of blood draws, and small sample sizes in individual cohorts. The finding does not invalidate AMH as a counseling tool, but it cautions against treating a single blood test as a crystal ball.

The methodological rigor of the analysis deserves attention. Risk of bias was assessed using the revised Cochrane RoB 2 tool for randomized trials and the ROBINS-I instrument for non-randomized studies of interventions, and the protocol was prospectively registered on PROSPERO under identifier CRD420261343270. Subgroup analyses explored sources of variation among the included studies. Still, the remarkably wide confidence intervals around the 24-month and 60-month recovery estimates signal substantial between-study heterogeneity, driven by differences in chemotherapy regimens, definitions of recovery, whether women were taking tamoxifen, and the sensitivity of hormonal assays used to define menopause.

That last point is more than a technical quibble. Aromatase inhibitors given with ovarian suppression, and tamoxifen itself, complicate the interpretation of amenorrhea in hormone receptor-positive breast cancer, since these agents alter menstrual patterns and endocrine markers. Landmark trials such as SOFT and TEXT demonstrated the value of ovarian suppression in premenopausal endocrine therapy, while ASTRRA substudies documented menstrual recovery patterns over five years in women taking tamoxifen after chemotherapy. Disentangling genuine ovarian failure from drug-induced amenorrhea remains one of the hardest problems in this literature, and it partly explains why pooled estimates vary so widely.

What should a newly diagnosed 35-year-old take from these numbers? First, she should know that loss of ovarian function after chemotherapy is the expected outcome rather than the exception, and full recovery is the minority experience. Second, age is destiny in this context: the younger she is at treatment, the better her chances of resuming ovarian activity. Third, the window for action closes the moment treatment begins. The authors emphasize that ovarian function recovery is an important treatment-related outcome that belongs in pretreatment counseling, encompassing early discussions of reproductive risk, multidisciplinary oncofertility consultation, and consideration of established fertility preservation methods, such as oocyte or embryo cryopreservation, before cancer-directed therapy starts. Temporary ovarian suppression with gonadotropin-releasing hormone agonists during chemotherapy, evaluated in trials like the POEMS and PROMISE studies, offers a partial protective option that modern guidelines from ASCO and ESMO now endorse as an adjunct, though it does not replace embryo or oocyte banking.

The meta-analysis does not end the scientific debate. It cannot answer whether recovered ovarian function translates into retained fertility, since resumption of menses is an imperfect proxy for reproductive capacity, and many women in the included studies never attempted pregnancy. It also cannot fully resolve how AMH, antral follicle counts, and ovarian volume should be combined into prediction models. But by assembling more than 10,000 patient journeys into a single quantitative framework, the study transforms vague reassurances such as sometimes periods come back into honest, data-driven estimates. For oncologists, fertility specialists, and the young women caught between curing their cancer and preserving their reproductive futures, that clarity is precisely the kind of evidence that changes conversations in the consultation room.

Subject of Research: Recovery of ovarian function after chemotherapy in premenopausal women with breast cancer

Article Title: Recovery of ovarian function after chemotherapy in premenopausal women with breast cancer: a systematic review and meta-analysis

Article References: Huynh, P. Y., Tran, B. V., Ngo, V. T., & Tran, T. T. (2026). Recovery of ovarian function after chemotherapy in premenopausal women with breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 219(3), Article 20. https://doi.org/10.1007/s10549-026-08083-4

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08083-4

Keywords: breast cancer, chemotherapy, ovarian function recovery, premenopausal women, fertility preservation, anti-Müllerian hormone, chemotherapy-induced amenorrhea, menopause, oncofertility, systematic review, meta-analysis, ovarian reserve

Blanchard’s story begins with a diagnosis that upended the ordinary timeline of a young life. Early-stage breast cancer in adolescents and young adults is relatively uncommon, but when it occurs, it forces patients to confront questions that most people their age never have to consider. Among the most pressing is fertility. Chemotherapy, endocrine therapy and other components of modern breast cancer treatment can impair ovarian function, and for hormone receptor-positive disease, the standard of care typically includes years of endocrine therapy such as tamoxifen, during which pregnancy is generally discouraged. For a young survivor who hopes to have children, this creates a collision between two goals that feel equally urgent: protecting herself from recurrence and preserving the possibility of motherhood.

For Blanchard, that collision became concrete in the form of a decision about a therapy break. Endocrine therapy for breast cancer is usually recommended for five to ten years, and its protective effect depends on continuous adherence. Yet young survivors who want to become pregnant must often consider pausing treatment, a prospect that raises the specter of recurrence. In her account, Blanchard describes the fear that accompanied this calculus, the sense that choosing family planning might mean gambling with her own survival. That fear, she writes, shadowed every conversation with her care team and every milestone in her treatment. The emotional weight of weighing a possible cancer recurrence against a possible pregnancy is, in her telling, one of the defining burdens of young survivorship.

The clinical framework for these decisions has evolved considerably in recent years. Studies of pregnancy after breast cancer have generally been reassuring, showing that survivors who become pregnant after treatment do not appear to face a substantially elevated risk of recurrence compared with similar patients who do not become pregnant. This evidence underpins the growing practice of offering carefully supervised endocrine therapy pauses, sometimes lasting up to two years, to selected young survivors who wish to try to conceive. The strategy, studied in prospective trials, allows a window for pregnancy while monitoring closely for signs of the disease returning. But the clinical reassurance that such pauses are reasonably safe does not erase the psychological toll of making the choice, and Blanchard’s reflection makes clear that the data and the dread coexist uneasily.

What her account adds to the literature is the part that rarely appears in clinical papers: the experience of pregnancy loss after cancer. Blanchard describes a series of losses following her diagnosis, each one compounding the grief of the last and entangling itself with her cancer history. For many survivors, a miscarriage is not only the loss of a pregnancy but an occasion for self-interrogation. Did the treatment damage my eggs? Did the endocrine therapy leave my body unable to sustain a pregnancy? Did I wait too long, or act too soon? In the absence of clear information, survivors often fill the silence with blame, and Blanchard’s title, addressed to herself and to others in her position, is a direct rebuttal: this is not your fault.

The medical evidence offers some support for that reassurance, though it is incomplete. Pregnancy loss is common in the general population, with a substantial fraction of recognized pregnancies ending in miscarriage, most often because of chromosomal abnormalities in the embryo that have nothing to do with the mother’s health or history. There is no strong evidence that prior breast cancer treatment, or a supervised break from endocrine therapy, dramatically increases the risk of miscarriage, although chemotherapy can reduce ovarian reserve and some treatments can affect the uterine environment. The honest answer to a survivor asking whether her cancer caused her pregnancy loss is usually that there is no reason to believe it did, and every reason to believe the loss was the kind of random biological event that occurs in millions of pregnancies. But that answer requires someone to deliver it, and Blanchard’s piece suggests that too often, no one does.

This is where her reflection turns from memoir to advocacy. In the implications section accompanying her account, she argues that adolescent and young adult cancer survivors should be offered counseling on fertility and family planning options at the time of diagnosis, not after treatment is complete, and that this support should continue throughout treatment and survivorship. The timing matters because many fertility preservation options, such as egg or embryo freezing, are only feasible before gonadotoxic therapy begins. But the argument extends beyond preservation. Survivors need ongoing conversations about when and how to safely pursue pregnancy, what the evidence says about therapy pauses, what monitoring is appropriate during and after pregnancy, and how to interpret pregnancy losses that occur along the way. Fertility, in this framing, is not a single decision point but a thread that runs through the entire survivorship experience.

The journal’s editors treated Blanchard’s reflection as more than a personal essay. In an accompanying editor’s note, associate editors Mark Lustberg and Sarah Hannum describe how her experience prompted them to invite, independently, experts in oncofertility to review the latest evidence on fertility management in breast cancer survivors. The result is a companion scoping review by Rajput, Cathcart-Rake, Ruddy and colleagues, published in the same journal, that systematically maps the evidence base on fertility in breast cancer survivorship. The pairing is deliberate: a first-person account of what the decisions feel like, placed alongside a rigorous synthesis of what the evidence shows. Together, they model the kind of dual attention, to patient experience and to clinical data, that the authors argue survivorship care requires.

The broader context makes the stakes clear. Survival rates for early breast cancer in young women are high, which means a growing population of survivors is living for decades after treatment, entering the years in which family building would ordinarily occur. Fertility preservation referral rates remain inconsistent across cancer centers, and surveys of young survivors repeatedly find gaps in knowledge about reproductive options and lingering uncertainty about the safety of pregnancy after cancer. Meanwhile, the psychological literature documents elevated rates of anxiety, depression and reproductive grief among survivors who experience infertility or pregnancy loss, with some evidence that the distress is amplified when patients attribute the loss to their cancer or its treatment. Blanchard’s insistence that the loss was not her fault speaks directly to that attribution, which clinicians can address but often do not.

Her reflection also carries a message about identity after cancer. Blanchard continued working as a physical therapist throughout her treatment and recovery, supporting other patients recovering from cancer diagnoses, and she frames that work as part of how she made meaning of her own experience. The piece is, in the end, an argument for a kind of honesty in medicine: that survivors are served not only by protocols and survival statistics but by clinicians willing to talk about the desire for children, the fear of recurrence, the grief of loss and the guilt that patients so often carry without being told to set it down. For the young survivors who will follow her through the same terrain, her account offers both a warning about what is missing from current care and a measure of the reassurance she herself had to construct alone.

Subject of Research: Fertility, family planning and pregnancy loss after breast cancer in adolescent and young adult survivors

Article Title: This is not your fault: a reflection on cancer and pregnancy loss

Article References: This is not your fault: a reflection on cancer and pregnancy loss. (n.d.). https://doi.org/10.1007/s11764-026-02121-2

Image Credits: AI Generated

DOI: 10.1007/s11764-026-02121-2

Keywords: breast cancer, cancer survivorship, fertility, pregnancy loss, endocrine therapy, family planning, adolescent and young adult cancer, infertility, oncofertility, recurrence fear, reproductive medicine, your